These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16566432)

  • 21. Cell line issues: historical and future perspectives.
    Petricciani JC
    Dev Biol Stand; 1992; 76():5-11. PubMed ID: 1478355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA vaccines: safety aspect assessment and regulation.
    Medjitna TD; Stadler C; Bruckner L; Griot C; Ottiger HP
    Dev Biol (Basel); 2006; 126():261-70; discussion 327. PubMed ID: 17058502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Children's questions: a mechanism for cognitive development.
    Chouinard MM
    Monogr Soc Res Child Dev; 2007; 72(1):vii-ix, 1-112; discussion 113-26. PubMed ID: 17394580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Translational research on vaccines: influenza as an example.
    Belshe RB
    Clin Pharmacol Ther; 2007 Dec; 82(6):745-9. PubMed ID: 17971813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proposed algorithm to investigate latent and occult viruses in vaccine cell substrates by chemical induction.
    Khan AS; Ma W; Ma Y; Kumar A; Williams DK; Muller J; Ma H; Galvin TA
    Biologicals; 2009 Jun; 37(3):196-201. PubMed ID: 19299169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccines and biosimilarity: a solution or a problem?
    Corbel MJ; Cortes Castillo Mde L
    Expert Rev Vaccines; 2009 Oct; 8(10):1439-49. PubMed ID: 19803764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological safety concepts of genetically modified live bacterial vaccines.
    Frey J
    Vaccine; 2007 Jul; 25(30):5598-605. PubMed ID: 17239999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Production of vaccines against leading biowarfare toxins can utilize DNA scientific technology.
    Middlebrook JL
    Adv Drug Deliv Rev; 2005 Jun; 57(9):1415-23. PubMed ID: 15896873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Manufacturing and quality control of cell-based tumor vaccines: a scientific and a regulatory perspective.
    Hinz T; Buchholz CJ; van der Stappen T; Cichutek K; Kalinke U
    J Immunother; 2006; 29(5):472-6. PubMed ID: 16971803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioreactor systems for the production of biopharmaceuticals from animal cells.
    Warnock JN; Al-Rubeai M
    Biotechnol Appl Biochem; 2006 Jul; 45(Pt 1):1-12. PubMed ID: 16764553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. WHO informal consultation on the scientific basis of specifications for production and control of inactivated Japanese encephalitis vaccines for human use, Geneva, Switzerland, 1-2 June 2006.
    Ferguson M; Kurane I; Wimalaratne O; Shin J; Wood D;
    Vaccine; 2007 Jul; 25(29):5233-43. PubMed ID: 17590244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus.
    Delecluse HJ; Feederle R; Behrends U; Mautner J
    Semin Cancer Biol; 2008 Dec; 18(6):409-15. PubMed ID: 18938248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Administration of tumor cell chromatin to immunosuppressed and non-immunosuppressed non-human primates.
    Wierenga DE; Cogan J; Petricciani JC
    Biologicals; 1995 Sep; 23(3):221-4. PubMed ID: 8527121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccines for minor use and minor species (MUMS)--industry's views.
    Bönisch B
    Dev Biol (Basel); 2004; 117():105-10. PubMed ID: 15597625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Industry perspective for biotech products.
    Möritz A
    Dev Biol (Basel); 2004; 118():37-44. PubMed ID: 15645671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant viral vectors: cancer vaccines.
    Harrop R; John J; Carroll MW
    Adv Drug Deliv Rev; 2006 Oct; 58(8):931-47. PubMed ID: 17030074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dendritic cell vaccines in melanoma: from promise to proof?
    Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
    Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems.
    Gottwein JM; Bukh J
    Adv Virus Res; 2008; 71():51-133. PubMed ID: 18585527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII.
    Ramanathan MP; Kutzler MA; Kuo YC; Yan J; Liu H; Shah V; Bawa A; Selling B; Sardesai NY; Kim JJ; Weiner DB
    Vaccine; 2009 Jul; 27(32):4370-80. PubMed ID: 19497647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of biological products prepared from mammalian cell culture. DNA.
    Dev Biol Stand; 1998; 93():136-8. PubMed ID: 9737393
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.